155 related articles for article (PubMed ID: 23563593)
1. C333H ameliorated insulin resistance through selectively modulating peroxisome proliferator-activated receptor γ in brown adipose tissue of db/db mice.
Zhang N; Chen W; Zhou X; Zhou X; Xie X; Meng A; Li S; Wang L
Biol Pharm Bull; 2013; 36(6):980-7. PubMed ID: 23563593
[TBL] [Abstract][Full Text] [Related]
2. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
Xu C; Wang LL; Liu HY; Zhou XB; Cao YL; Li S
Acta Pharmacol Sin; 2006 Feb; 27(2):223-8. PubMed ID: 16412273
[TBL] [Abstract][Full Text] [Related]
3. A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice.
Wu D; Eeda V; Undi RB; Mann S; Stout M; Lim HY; Wang W
Mol Metab; 2021 Dec; 54():101363. PubMed ID: 34710641
[TBL] [Abstract][Full Text] [Related]
4. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
Xie X; Zhou X; Chen W; Long L; Li W; Yang X; Li S; Wang L
Biochim Biophys Acta; 2015 Jan; 1850(1):62-72. PubMed ID: 25305559
[TBL] [Abstract][Full Text] [Related]
5. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats.
Yang B; Brown KK; Chen L; Carrick KM; Clifton LG; McNulty JA; Winegar DA; Strum JC; Stimpson SA; Pahel GL
BMC Pharmacol; 2004 Oct; 4():23. PubMed ID: 15491498
[TBL] [Abstract][Full Text] [Related]
6. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
7. Long-term nitrate administration increases expression of browning genes in epididymal adipose tissue of male type 2 diabetic rats.
Jeddi S; Yousefzadeh N; Afzali H; Ghasemi A
Gene; 2021 Jan; 766():145155. PubMed ID: 32950634
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptors-α and -γ, and cAMP-mediated pathways, control retinol-binding protein-4 gene expression in brown adipose tissue.
Rosell M; Hondares E; Iwamoto S; Gonzalez FJ; Wabitsch M; Staels B; Olmos Y; Monsalve M; Giralt M; Iglesias R; Villarroya F
Endocrinology; 2012 Mar; 153(3):1162-73. PubMed ID: 22253419
[TBL] [Abstract][Full Text] [Related]
9. Brown Adipose Tissue PPARγ Is Required for the Insulin-Sensitizing Action of Thiazolidinediones.
Shibata Y; Eguchi J; Wada J
Acta Med Okayama; 2023 Jun; 77(3):243-254. PubMed ID: 37357625
[TBL] [Abstract][Full Text] [Related]
10. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
Hiuge-Shimizu A; Maeda N; Hirata A; Nakatsuji H; Nakamura K; Okuno A; Kihara S; Funahashi T; Shimomura I
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):792-9. PubMed ID: 21233451
[TBL] [Abstract][Full Text] [Related]
11. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
12. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
[TBL] [Abstract][Full Text] [Related]
13. The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Pruimboom-Brees IM; Francone O; Pettersen JC; Kerlin RL; Will Y; Amacher DE; Boucher GG; Morton D
Toxicol Pathol; 2012 Jul; 40(5):810-8. PubMed ID: 22504321
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
[TBL] [Abstract][Full Text] [Related]
15. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
[TBL] [Abstract][Full Text] [Related]
16. A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.
Jeong HW; Lee JW; Kim WS; Choe SS; Kim KH; Park HS; Shin HJ; Lee GY; Shin D; Lee H; Lee JH; Choi EB; Lee HK; Chung H; Park SB; Park KS; Kim HS; Ro S; Kim JB
Diabetes; 2011 Feb; 60(2):496-506. PubMed ID: 21270261
[TBL] [Abstract][Full Text] [Related]
17. Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
Iwai M; Kanno H; Inaba S; Senba I; Sone H; Nakaoka H; Horiuchi M
Am J Hypertens; 2011 Feb; 24(2):169-74. PubMed ID: 20847723
[TBL] [Abstract][Full Text] [Related]
18. Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity.
Rangwala SM; Rhoades B; Shapiro JS; Rich AS; Kim JK; Shulman GI; Kaestner KH; Lazar MA
Dev Cell; 2003 Oct; 5(4):657-63. PubMed ID: 14536066
[TBL] [Abstract][Full Text] [Related]
19. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
